Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APF530 for CINV in HEC Patients
NCT02106494Phase 3Completed
- Sponsor
- Heron Therapeutics, Inc.
- Start
- Mar 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of granisetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Heron Therapeutics, Inc.. Started Mar 2014; status: completed.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02106494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106494.